CNBXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:42):

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer...

Stats
本日の出来高	1.21M
平均出来高	244 842
時価総額	336 003
EPS	$0 ( 2024-04-14 )
次の収益日	( $0 ) 2024-07-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0.0100
ATR14	$0.00100 (9.26%)

Insider Trading

Date	Person	Action	Amount	type
2014-07-25	Cannabics Inc.	Buy	18 239 594	COMMON STOCK
2014-06-23	Cannabics Inc.	Buy	14 525 000	Common Stock
2014-05-08	Cannabics Inc.	Buy	20 500 000	Common Stock
2014-05-08	Mills Thomas E	Sell	20 500 000	common stock
2014-04-25	Mills Thomas E	Buy	20 500 000	common stock

INSIDER POWER
0.00
Last 15 transactions
Buy: 135 764 594 \| Sell: 73 500 000

Cannabics Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cannabics Pharmaceuticals 財務諸表

Annual	2023
収益:	$410 165
総利益:	$248 104 (60.49 %)
EPS:	$-0.420

FY	2023
収益:	$410 165
総利益:	$248 104 (60.49 %)
EPS:	$-0.420

FY	2022
収益:	$29 958.00
総利益:	$-168 569 (-562.68 %)
EPS:	$-3.08

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.0200

Financial Reports:

No articles found.

Cannabics Pharmaceuticals

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.